- Home
- BOLT vs PULM Comparison
BOLT vs PULM Comparison
Compare BOLT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- PULM
- Stock Information
- Founded
- BOLT 2015
- PULM 2003
- Country
- BOLT United States
- PULM United States
- Employees
- BOLT N/A
- PULM N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- PULM Health Care
- Exchange
- BOLT Nasdaq
- PULM Nasdaq
- Market Cap
- BOLT 22.6M
- PULM 21.0M
- IPO Year
- BOLT 2021
- PULM N/A
- Fundamental
- Price
- BOLT $0.49
- PULM $7.10
- Analyst Decision
- BOLT Hold
- PULM
- Analyst Count
- BOLT 5
- PULM 0
- Target Price
- BOLT $1.25
- PULM N/A
- AVG Volume (30 Days)
- BOLT 136.2K
- PULM 37.6K
- Earning Date
- BOLT 03-20-2025
- PULM 03-27-2025
- Dividend Yield
- BOLT N/A
- PULM N/A
- EPS Growth
- BOLT N/A
- PULM N/A
- EPS
- BOLT N/A
- PULM N/A
- Revenue
- BOLT $9,779,000.00
- PULM $10,005,000.00
- Revenue This Year
- BOLT $9.87
- PULM N/A
- Revenue Next Year
- BOLT N/A
- PULM $1.00
- P/E Ratio
- BOLT N/A
- PULM N/A
- Revenue Growth
- BOLT 35.86
- PULM 47.05
- 52 Week Low
- BOLT $0.46
- PULM $1.55
- 52 Week High
- BOLT $1.56
- PULM $8.44
- Technical
- Relative Strength Index (RSI)
- BOLT 44.93
- PULM 62.30
- Support Level
- BOLT $0.49
- PULM $6.84
- Resistance Level
- BOLT $0.52
- PULM $8.14
- Average True Range (ATR)
- BOLT 0.03
- PULM 0.39
- MACD
- BOLT -0.00
- PULM 0.11
- Stochastic Oscillator
- BOLT 24.24
- PULM 71.43
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.